CClinicalTrials.gg
CompletedNCT03409640Updated Jan 24, 2018

Metal-on-metal Hip Replacement MRI Study

An observational study in Hip Athroplasty Using M2a Magnum, sponsored by Zimmer Biomet. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This study is being conducted to determine the rate of symptomatic and asymptomatic nonmalignant, noninfective soft tissue mass presence (referred to in the literature as pseudotumour, ALVAL, ARMD, cysts or lesions) in primary metal on metal hip replacement patients. The primary objective of the study is to determine the prevalence of masses in unbiased Metal on Metal (MoM) samples drawn from one study centre. The subjects receiving the Metal on Metal devices will be observed at two specific time points. Secondary objectives are to evaluate whether the occurrence of masses is related to any of several potential factors including patient and implant characteristics and time since the implant procedure took place.

02

Conditions studied

  • Hip Athroplasty Using M2a Magnum
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients receiving either the M2a Magnum or M2a 38mm Metal on Metal primary hip replacement devices from a single study centre.

Inclusion criteria

  • Patients implanted with the M2a Magnum who were evaluated via MRI and metal ion analysis between 2012 and 2013.

Exclusion criteria

Exclusion Criteria:

  • If the primary device was implanted for less than 36 months (in the case of patients already revised) or has been in place for less than 36 months (in the case of patients with the device still in place).
  • If the patient is contraindicated for any of the diagnostic tests.
  • If the patient fails to consent to participating in the study.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. MRI Scoring change in soft tissue mass size

    MRI Score - monitor number and size of soft tissue lesions

    Time frame: 36 months after primary device implantation

Secondary outcomes

  1. Radiographic assessment

    Assess acetabular cup inclincation and version

    Time frame: 36 months after primary device implantation

  2. Oxford Hip Score

    Oxford Hip Score, score range 0 (worst) to 48 (best)

    Time frame: 36 months after primary device implantation

  3. UCLA Activity Score

    UCLA activity scale, range: 1 defined as "no physical activity, dependent on others" to 10 defined as "regular participation in impact sports."

    Time frame: 36 months after primary device implantation

  4. EQ-5D

    EQ-5D Index score; Patient Reported Outcome

    Time frame: 36 months after primary device implantation

  5. Metal Ion Levels

    Chromium and Cobalt metal ion levels in blood

    Time frame: 36 months after primary device implantation

06

Study locations

1 site
  • Basingstoke and North Hampshire Hospital
    Basingstoke, RG24 9NA, United Kingdom
07

Registry details

Key details

Study ID
NCT03409640
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Jan 17, 2014
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017
Last update
Jan 24, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion